



## Spruce Biosciences to Participate in Upcoming Investor Conferences

February 17, 2021

SAN FRANCISCO--(BUSINESS WIRE)--Feb. 17, 2021-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that the company will participate in two upcoming investor conferences.

### **10<sup>th</sup> Annual SVB Leerink Global Healthcare Conference**

Chief Executive Officer, Richard King, is scheduled to participate in a fireside chat on Wednesday, February 24 at 9:00am PST / 12:00pm EST.

### **41<sup>st</sup> Cowen Annual Healthcare Conference**

Richard King is also scheduled to participate in a panel discussion on Tuesday, March 2 at 11:10am PST / 2:10pm EST.

Interested parties can access the live webcast for each conference from the Investor Relations section of the company's website at [www.sprucebiosciences.com](http://www.sprucebiosciences.com). A replay of the webcasts will be available after the conclusion of the live presentation for approximately 30 days.

### **About Spruce Biosciences**

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210217005024/en/): <https://www.businesswire.com/news/home/20210217005024/en/>

### **Media**

Will Zasadny  
Canale Communications  
(619) 961-8848  
[will@canalecomm.com](mailto:will@canalecomm.com)  
[media@sprucebiosciences.com](mailto:media@sprucebiosciences.com)

### **Investors**

Thomas Hoffmann  
Solebury Trout  
(646) 378-2931  
[thoffmann@soleburytrout.com](mailto:thoffmann@soleburytrout.com)  
[investors@sprucebiosciences.com](mailto:investors@sprucebiosciences.com)

Source: Spruce Biosciences, Inc.